Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study-Reference-Cited by-同舟云学术

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Published:2021-12 Issue:12 Volume:8 Page:e891-e901
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Diefenbach Catherine,Kahl Brad S,McMillan Andrew,Briones Javier,Banerjee Lalita,Cordoba Raul,Miall Fiona,Burke John M,Hirata Jamie,Jiang Yanwen,Paulson Joseph N,Chang Yi Meng,Musick Lisa,Abrisqueta Pau

Funder

F. Hoffmann-La Roche Ltd

Genentech Inc

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Burden of illness of follicular lymphoma and marginal zone lymphoma;Monga;Ann Hematol,2019

2. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study;Casulo;J Clin Oncol,2015

3. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs;Matasar;The oncologist,2019

4. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol,2016

5. Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries;Lancet,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and future therapies for follicular lymphoma;Experimental Hematology & Oncology;2024-08-22

2. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma;Cancers;2024-02-18

3. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study;The Lancet Haematology;2024-02

4. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

5. Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial;2024